MedinCell SA MEDCL

MONTPELLIER, France, September 30, 2026--Regulatory News: Medincell's (Paris:MEDCL) Annual General Meeting will be held as scheduled today at 6:00 p.m. at the Company's headquarters.

MONTPELLIER, France, September 21, 2026--Medincell's partner Teva presented new data on investigational Olanzapine long-acting injectable (LAI) and UZEDY®, two treatments utilizing Medincell's proprietary BEPO® technology, licensed to Teva as SteadyTeq™. The findings were presented at Psych Congress 2026, held from September 15 to 19 in New Orleans, Louisiana.

MONTPELLIER, France, September 09, 2026--Regulatory News: Medincell (Euronext Paris: MEDCL), a commercial- and clinical-stage biopharmaceutical licensing company developing long-acting injectable treatments, today announced its participation in the following September 2026 investor conferences by Dr Grace Kim, Chief Strategy Officer, U.S. Finance.

MONTPELLIER, France, September 08, 2026--Regulatory News: Medincell (Paris:MEDCL):

MONTPELLIER, France, September 01, 2026--Medincell (Euronext: MEDCL), a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable treatments across multiple therapeutic areas, today announced the appointment of Edna Venneker, MD, as Chief Medical Officer.

MONTPELLIER, France, August 11, 2026--Regulatory News: Medincell (Euronext Paris: MEDCL), a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, announced today that Dr Grace Kim, Chief Strategy Officer, U.S. Finance, will take part in the annual Piper Sandler CNS Symposium Thursday, August 13, 2026.

MONTPELLIER, France, July 29, 2026--Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously.

MONTPELLIER, France, July 29, 2026--Regulatory News: Medincell (Euronext Paris: MEDCL) partner, Teva Pharmaceuticals (NYSE and TASE: TEVA), announced today that UZEDY® U.S. net sales reached a record $77 million in Q2 2026, up 43% year-on-year. Teva raised its 2026 UZEDY® revenue outlook to $270 million–$290 million, from $250 million–$280 million previously.

MONTPELLIER, France, July 28, 2026--Regulatory News: Medincell (Paris:MEDCL):

MONTPELLIER, France, July 28, 2026--Medincell (Euronext Paris: MEDCL) today announced that its Board of Directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director at the Company's Annual General Meeting on September 30, 2026. A highly experienced international life sciences executive, Dr. Svanberg would bring deep expertise in global pharmaceutical development, governance, executive compensation and global health as Medincell advances its next phase of growth.

MONTPELLIER, France, July 15, 2026--Regulatory News: Medincell (Euronext Paris: MEDCL) today announced the completion of non-dilutive financing transactions designed to strengthen its financing profile and align debt maturities with the Company's expected revenue growth trajectory and future cash flows. These cash flows are expected to be primarily driven by milestones and royalties from UZEDY®, which is already marketed, and from Olanzapine LAI, currently under regulatory review in the U.S., wi

MONTPELLIER, France, July 06, 2026--Regulatory News: Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2026:

MONTPELLIER, France, June 16, 2026--Regulatory News: Medincell (Paris:MEDCL):